FRONTIER BIOTECHNOLOGIES Inc.

Press Releases

 
Home>Media
On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang.Aiming at intelligent manufacturing, high efficiency and eco syst...
  • 2021-08-31  16:54:43
details>
Nanjing, China, October 28, 2020 -- Frontier Biotechnologies Inc.( Frontier Biotech), a commercial-stage biopharmaceutical company focused on discovering, development, manufacturing, and commercialization of innovative medicines, today announced its completion of the Initial Public Offering (IPO) an...
  • 2020-10-28  09:04:39
details>
July 21, 2021 Nanjing, China. Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. Cheryl Tan, Global H...
  • 2021-08-30  15:52:59
details>
Frontier Biotech (688221.SH) recently received the Certificate of Registration of Foreign Medicines issued by the Ministry of Health of Ecuador for companys innovative anti-HIV drug AikeningTM (Albuvirtide for injection 160 mg) to be marketed in Ecuador.AlfusidTM is the registered trade mark of Aike...
  • 2021-03-18  19:58:20
details>
Nanjing, China, Nov 7th, 2019 - Frontier Biotechnologies, Inc. (Frontier Biotech) announced that US Food and Drug Administration (USFDA) has granted the Fast Track designation (FTD) to its all-injectable anti-HIV two-drug combination of 3BNC117 and Aikening® for the treatment of multidrug-resis...
  • 2019-11-07  11:15:06
details>
NanjingSep. 26th, 2019 Frontier Biotechnologies (“Frontier Biotech”), a biopharmaceutical company headquartered in China, focusing on innovative drug development for anti-HIV treatment and pain management, and Thermo Fisher Scientific, the world leader in serving science, announced that they have en...
  • 2019-09-29  16:26:53
details>
August 21, 2018 Nanjing, ChinaFrontier Biotech announced today its IND of novel long-acting, all-injectable anti-HIV two drug combo (albuvirtide for injection, ABT and 3BNC117) was allowed by the US FDA on August 14th 2018, and the company will start a phase II clinical trial of the combo therapy in...
  • 2018-08-21  11:00:35
details>
The HIV Forum on "NAbs and Functional Cure" was successfully held by Tsinghua University and Frontier Biotech on Nov 28, 2017 in Beijing. Coming with the 30th World AIDS Day, this event was focused on the latest research of broad neutralizing antibodies (bNAbs) and long-acting drug regimen...
  • 2017-12-20  10:58:36
details>

Develop Innovative Therapies to Better Human Lives